Patent issued for alleviating pain research in cattle

Patent covers administering meloxicam alone or in combination with gabapentin to help alleviate acute and chronic pain in cattle.

A U.S. patent was recently awarded for technology created by researchers at Kansas State University that improves the health and welfare of beef cattle and other ruminant animals suffering from lameness and following castration, dehorning and other painful but necessary management procedures.

U.S. Patent No. 8,791,105, "Methods for Alleviating Chronic Pain & Improving Performance of Cattle Undergoing Dehorning or Castration," was awarded to the Kansas State University Research Foundation, a nonprofit corporation responsible for managing technology transfer activities at the university.

The patent is for research conducted while at Kansas State University by former faculty member Hans Coetzee, now a professor of clinical pharmacology at Iowa State University, and Butch Kukanich, associate professor of anatomy and physiology at Kansas State University.

According to the announcement, the patent covers administering meloxicam alone or administering a combination of meloxicam and gabapentin to help alleviate acute and chronic pain and improve the performance of cattle. Researchers found that combinations of meloxicam and gabapentin improved the welfare of cattle by reducing the severity of lameness. Meloxicam alone improved weight gain after dehorning and reduced the incidence of bovine respiratory disease after castration.

"Once meloxicam was orally administered to beef cattle prior to these common procedures, the cattle gained more weight and had slower incidence of bovine respiratory disease because it allowed them to be more comfortable and less stressed," Kukanich said.

A significant benefit of this patented technology is that it reduces reliance on antibiotics to treat and control diseases in cattle. This reduces the risk of antibiotic resistance selection and has positive implications for both human and animal health, the announcement said.

The patent is available to license.

Hide comments

Comments

  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Publish